Synthon B.v.

Marta Vivancos Martinez

Lisardo Alvarez Fernandez

Jose Velada Calzada

Luis Nogueiras Nieto

Deepak Murpani

Rohit Kumar

Rolf Keltjens

Jacobus Theodorus Henricus Van Eupen

Petr Mitas

Bohumil Dymacek

Lisardo ÁLvarez FERNÁNDEZ

Jacobus Theodorus Henricus Eupen Van

The present invention relates to a pharmaceutical granulate composition comprising Palbociclib free base, having improved bioavailability.

Pharmaceutical composition comprising Palbociclib

The present invention relates to a pharmaceutical composition comprising amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, with a synthetic antioxidant and one or more pharmaceutically acceptable excipients. The invention further relates to the process to manufacture such a compositions and the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodyplastic syndromes.

Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant

The present invention relates to a pharmaceutical composition comprising a physical mixture of sacubitril sodium and valsartan disodium, wherein the X-ray powder diffraction pattern of valsartan disodium comprises characteristic peaks at the following 2 theta (&#xb1;0.2) angles: 4.70&#xb0;, 9.29&#xb0;, 22.34&#xb0;, measured using a Cu K&#x3b1; radiation. The invention further relates to the use of said pharmaceutical composition as medicament in the treatment of heart failure.

Pharmaceutical composition comprising sacubitril and valsartan

The present invention relates to a pharmaceutical composition comprising an amorphous adsorbate of lenalidomide, or a pharmaceutically acceptable salt thereof, on a porous carrier and one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of multiple myeloma and myelodysplastic syndromes.

Pharmaceutical composition comprising amorphous lenalidomide

The present invention relates to a pharmaceutical composition comprising an inclusion complex of amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, in non-substituted &#x3b2;-cyclodextrin and one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodysplastic syndromes.

The present invention relates to a tablet composition comprising a therapeutically effective dose of cinacalcet hydrochloride having a particle size distribution Dequal to or less than 30 &#x3bc;m in an amount of from 40% to 60% by weight based on the total weight of the composition, and one or more pharmaceutically acceptable excipients.

Growing community of inventors

Sant Boi de Llobregat, Spain

Marta Vivancos Martinez